A Study of the Safety and Tolerability of the Addition of CHR-2797 to Paclitaxel in Patients With Advanced or Refractory Tumours

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00737555
Recruitment Status : Completed
First Posted : August 19, 2008
Last Update Posted : February 15, 2012
Information provided by (Responsible Party):
Chroma Therapeutics

Brief Summary:
The treatment of cancer often involves the use of more than one drug at the same time. In this study, patients are treated with the already marketed drug paclitaxel (administered every 3 weeks by infusion)and with the investigational drug CHR-2797 (given orally, once daily). The purpose of this study is to evaluate if it is safe to administer these two drugs together, and how well the combination is tolerated by patients. The first patients will receive a 90mg dose of CHR-2797; doses will be increased in subsequent patients, as long as they are adequately tolerated.

Condition or disease Intervention/treatment Phase
Solid Tumor Drug: CHR-2797 Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 23 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1b Dose-escalation Study to Evaluate the Safety and Tolerability of the Addition of the Aminopeptidase Inhibitor CHR-2797 to Paclitaxel in Patients With Advanced or Refractory Tumours
Study Start Date : August 2006
Actual Primary Completion Date : March 2008
Actual Study Completion Date : March 2008

Resource links provided by the National Library of Medicine

Drug Information available for: Paclitaxel

Arm Intervention/treatment
Experimental: 1
Once daily oral administration of CHR-2797 ( escalating dose groups) in solid tumour patients receiving paclitaxel infusion every three weeks
Drug: CHR-2797
Oral once daily administration of capsules of CHR-2797, to determine safety and tolerability in patients being treated with paclitaxel infusion every 3 weeks for up to 18 weeks.
Other Names:
  • Aminopeptidase inhibitor
  • Proposed INN: tosedostat

Primary Outcome Measures :
  1. To determine the safety, tolerability, dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of CHR-2797 when administered in combination with paclitaxel. [ Time Frame: 18 weeks ]

Secondary Outcome Measures :
  1. To evaluate the pharmacokinetic profile of the combination of CHR-2797 and paclitaxel and identify any pharmacokinetic interaction between the 2 agents. [ Time Frame: After 1st and 2nd infusion of paclitaxel ]
  2. To determine response and response duration, time to progressive disease or treatment failure during combination therapy and in those patients who continued beyond 18 weeks on monotherapy with CHR-2797. [ Time Frame: Maximum duration of patient treatment ( combination followed by monotherapy) was 9 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Signed, informed consent.
  • Age > 18 years
  • Histologically or cytologically documented locally advanced or metastatic solid tumour refractory to standard therapy or for which no standard therapy exists.
  • Patients should have recovered from the acute adverse effects of prior therapies (excluding alopecia).
  • Adequate bone marrow, hepatic and renal function including the following:
  • Hb > 9g/dl (transfusion independent) or >10g/dl (transfusion permitted), absolute neutrophil count > 1.5 x 109/L, platelets ≥ 100 x 109/L;
  • Total bilirubin ≤ 1.5 x upper normal limit;
  • AST (SGOT), ALT (SGPT) ≤ 2.5 x upper normal limit
  • Creatinine ≤1.5 x upper normal limit.
  • Performance status (PS) ≤ 2 (ECOG scale).
  • Estimated life-expectancy greater than 3 months.
  • Female patients with reproductive potential must have a negative serum pregnancy test within 7 days prior to start of trial. Both women and men must agree to use a medically acceptable method of contraception throughout the treatment period and for 3 months after discontinuation of treatment.

Exclusion Criteria:

  • Anti-cancer therapy including chemotherapy, radiotherapy, endocrine therapy, immunotherapy or use of other investigational agents within the 4 weeks prior to first dose of medication in this trial or within a longer period, depending on the defined characteristics of the agent e.g. 6 weeks for nitrosurea or mitomycin. Bisphosphonates for bone disease are permitted provided the doses are stable before and during the trial.
  • Co-existing active infection or serious concurrent illness.
  • Significant cardiovascular disease as defined by:

    • history of congestive heart failure requiring therapy;
    • history of unstable angina pectoris or myocardial infarction up to 6 months prior to trial entry;
    • presence of severe valvular heart disease;
    • presence of a ventricular arrhythmia requiring treatment.
  • Any co-existing medical condition that in the investigator's judgement will
  • substantially increase the risk associated with the patient's participation in the study.
  • Psychiatric disorders or altered mental status precluding understanding of the
  • informed consent process and/or completion of the necessary studies.
  • Gastrointestinal disorders that may interfere with absorption of the study drug.
  • Persistent grade II or greater toxicity from any cause.
  • Patients with known brain tumours or metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurological dysfunction that would confound the evaluation of neurologic and other adverse events.
  • More than 4 prior chemotherapy regimens.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00737555

UMC St Radboud
Nijmegen, Netherlands, 6525 GA
Erasmus MC University Medical Centre- Location Centrum
Rotterdam, Netherlands, 3015 CE
Sponsors and Collaborators
Chroma Therapeutics
Principal Investigator: Carla van Herpen UMC St Radboud
Principal Investigator: Ferry Eskens Erasmus MC University Medical Center

Additional Information:
Responsible Party: Chroma Therapeutics Identifier: NCT00737555     History of Changes
Other Study ID Numbers: CHR-2797-003
EudraCT# 2006-002498-35
First Posted: August 19, 2008    Key Record Dates
Last Update Posted: February 15, 2012
Last Verified: February 2012

Keywords provided by Chroma Therapeutics:
Solid tumour
Solid tumor
dose escalation

Additional relevant MeSH terms:
Albumin-Bound Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Glycine Agents
Neurotransmitter Agents
Physiological Effects of Drugs